Intriguingly, sorafenib reduced the expression of DDX5 in human HCC cell lines and preclinical HCC models, while overexpression of DDX5 in sorafenib-treated cells reduced viability by induction of ferroptosis. The gene discussed is DDX5; the disease is hepatocellular carcinoma.